Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.

The pharmacogenomics journal - 1 Feb 2014

Stevens A, Clayton P, Tatò L, Yoo H W, Rodriguez-Arnao M D, Skorodok J, Ambler G R, Zignani M, Zieschang J, Della Corte G, Destenaves B, Champigneulle A, Raelson J, Chatelain P

Abstract excerpt

Individual responses to growth hormone (GH) treatment are variable. Short-term generation of insulin-like growth factor-I (IGF-I) is recognized as a potential marker of sensitivity to GH treatment. This prospective, phase IV study used an integrated genomic analysis to identify markers associated with 1-month change in IGF-I (ΔIGF-I) following initiation of recombinant human (r-h)GH therapy in treatment-naïve...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 4
Share to Growth Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormone Replacement Therapy

Share to Human Growth Hormone

Share to Insulin-Like Growth Factor I

Share to Recombinant Proteins

Share to Transcriptome

Share to Turner Syndrome

Source

Open in PubMed Open full text

Identifiers

PMID: 23567489
DOI: 10.1038/tpj.2013.14
PMCID: PMC3959225

Genes

CDK4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of insulin-like growth factor-I generation during GH treatment in children with GH deficiency or Turner syndrome.PMID 23567489Read ↗

A pharmacogenomic approach to the treatment of children with GH deficiency or Turner syndrome.Semantic proximity Read ↗

The future of research into growth hormone responsiveness.Semantic proximity Read ↗

Growth hormone pharmacogenetics: the interactive effect of a microsatellite in the IGF1 promoter region with the GHR-exon 3 and -202 A/C IGFBP3 variants on treatment outcomes of children with severe GH deficiency.Semantic proximity Read ↗

Gene expression signatures predict response to therapy with growth hormoneSemantic proximity Read ↗

Gene expression signatures predict response to therapy with growth hormoneSemantic proximity Read ↗

Validating genetic markers of response to recombinant human growth hormone in children with growth hormone deficiency and Turner syndrome: the PREDICT validation study.Semantic proximity Read ↗

SNPs within the GH-signaling pathway are associated with the early IGF1 response to GH replacement therapy in GHD adults.Semantic proximity Read ↗

IGF-I in human growth: lessons from defects in the GH-IGF-I axis.Semantic proximity Read ↗

Risk of cancer in patients treated with recombinant human growth hormone in childhoodSemantic proximity Read ↗

The in vitro functional analysis of single-nucleotide polymorphisms associated with growth hormone (GH) response in children with GH deficiency.Semantic proximity Read ↗

Association of the (CA)n repeat polymorphism of insulin-like growth factor-I and -202 A/C IGF-binding protein-3 promoter polymorphism with adult height in patients with severe growth hormone deficiency.Semantic proximity Read ↗

Effect of single nucleotide polymorphisms on CDK4 and Zn supplementation in children with growth hormone deficiency.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.